In particular, use of antibiotics with anaerobic activity, given after initiation of PD-1/PD-L1 inhibitors, has been associated with an increased risk of more severe ICI-mediated diarrhea and/or colitis (IMDC) [21]. Here, PDCD1 is linked to colitis.